<DOC>
	<DOCNO>NCT00000715</DOCNO>
	<brief_summary>To compare safety effectiveness drug therapy aerosolize pentamidine ( PEN ) conventional therapy , sulfamethoxazole plus trimethoprim ( SMX/TMP ) treatment Pneumocystis carinii pneumonia ( PCP ) patient AIDS , HIV positive , high risk HIV infection . New treatment need PCP , common lung infection patient AIDS , many patient treat two standard treatment , PEN give injection SMX/TMP , adverse effect require change treatment . There also high relapse rate standard treatment . Preliminary experiment human suggest aerosolize PEN effective standard treatment PCP , cause adverse effect .</brief_summary>
	<brief_title>A Controlled Trial Comparing Efficacy Aerosolized Pentamidine Parenteral/Oral Sulfamethoxazole-Trimethoprim Treatment Pneumocystis Carinii Pneumonia AIDS</brief_title>
	<detailed_description>New treatment need PCP , common lung infection patient AIDS , many patient treat two standard treatment , PEN give injection SMX/TMP , adverse effect require change treatment . There also high relapse rate standard treatment . Preliminary experiment human suggest aerosolize PEN effective standard treatment PCP , cause adverse effect . Patients enter study randomly assign aerosolized PEN intravenous SMX/TMP , 21-day trial . SMX/TMP give 4 time day aerosolize PEN day . Doses determine body size . Patients receive aerosolize PEN also receive placebo intravenous injection patient receive SMX/TMP also receive placebo aerosol . Patients hospitalize least 5 day . Patients improve may discharge 5 day discretion attend physician . Discharged patient continue study oral SMX/TMP aerosolize placebo aerosolize PEN oral placebo . Patients fail respond develop severe adverse effect switch intravenous PEN standard therapy . During 21-day trial , zidovudine ( AZT ) may use . AZT may resume therapy acute PCP episode complete .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Inclusion Criteria Prior Medication : Allowed : Zidovudine ( AZT ) , must suspend study medication . Unequivocal diagnosis Pneumocystis carinii pneumonia establish morphologic confirmation three typical Pneumocystis carinii organism sputum , bronchoalveolar lavage fluid , lung tissue obtain transbronchial openlung biopsy within 3 day randomization . If morphologic confirmation possible prior therapy , patient may randomize investigator believe high suspicion PCP base clinical presentation . If morphologic diagnosis establish within 5 day randomization , patient withdrawn study therapy . Resting ( Aa ) DO2 le 30 torr room air ACTG sit except San Francisco General Hospital . NonACTG sit enter patient rest ( Aa ) DO2less 55 mmHg room air . Exclusion Criteria Coexisting Condition : Patients follow exclude : Dyspnea , cough , bronchospasm , reason cause inability cooperate aerosol administration . History major adverse reaction pentamidine sulfonamidecontaining preparation define : Absolute neutropenia 750 less PMN + band cells/mm3 . Thrombocytopenia 40000 platelets/mm3 . Rise creatinine : To 3.0 mg/dl . Liver function abnormality : SGOT SGPT great 5 x upper limit normal . Hypoglycemia 50 mg/dl . Rash : Exfoliative mucositis . Cough : Unremitting bronchospasm uncontrolled bronchodilator prevent 50 percent deliver dose 2 day . Concurrent Medication : Excluded : Other drug treatment prevention AIDS Pneumocystis carinii pneumonia . Zidovudine ( AZT ) . Patients follow exclude : Dyspnea , cough , bronchospasm , reason cause inability cooperate aerosol administration . History major adverse reaction pentamidine sulfonamidecontaining preparation define : Absolute neutropenia 750 less PMN + band cells/mm3 . Thrombocytopenia low 40000 platelets/mm3 . Rise creatinine : To great 3.0 mg/dl . Liver function abnormality : SGOT SGPT great 5 x upper limit normal . Hypoglycemia le 50 mg/dl . Rash : Exfoliative mucositis . Cough : Unremitting bronchospasm uncontrolled bronchodilator prevent 50 percent deliver dose 2 day . Prior Medication : Excluded within 14 day study entry : Systemic steroid higher adrenal replacement dos . Excluded within 6 week study entry : Another antiprotozoal regimen episode , whether therapeutic prophylactic . Sulfamethoxazole / trimethoprim . Pyrimethamine . Sulfadoxine / pyrimethamine . Pentamidine . Eflornithine .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Administration , Inhalation</keyword>
	<keyword>Aerosols</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>